Details

Autor(en) / Beteiligte

• Chang, Vicky C.
• Rhee, Jongeun
• Berndt, Sonja I.
• Moore, Steven C.
• Freedman, Neal D.
• Jones, Rena R.
• Silverman, Debra T.
• Gierach, Gretchen L.
• Hofmann, Jonathan N.
• Purdue, Mark P.

Titel

Serum perfluorooctane sulfonate and perfluorooctanoate and risk of postmenopausal breast cancer according to hormone receptor status: An analysis in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

Ist Teil von

• International journal of cancer, 2023-08, Vol.153 (4), p.775-782

Ort / Verlag

Hoboken, USA: John Wiley & Sons, Inc

Erscheinungsjahr

2023

Quelle

Wiley Online Library All Journals

Beschreibungen/Notizen

• Per‐ and polyfluoroalkyl substances (PFAS) are highly persistent endocrine‐disrupting chemicals that may contribute to breast cancer development; however, epidemiologic evidence is limited. We investigated associations between prediagnostic serum levels of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) and postmenopausal breast cancer risk, overall and by hormone receptor status, in a nested case‐control study of 621 cases and 621 matched controls in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. PFOS and PFOA levels were determined based on serum metabolomic profiling performed using ultraperformance liquid chromatography‐tandem mass spectrometry. We used multivariable conditional logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between each PFAS and breast cancer risk, overall, by estrogen receptor (ER) or progesterone receptor (PR) status, and by joint ER/PR status. We found little evidence of association between PFOS or PFOA and breast cancer risk overall. However, in subtype‐specific analyses, we observed statistically significant increased risks of ER+, PR+, and ER+/PR+ tumors for the third vs lowest quartile of serum PFOS (ORs [95% CIs] = 1.59 [1.01‐2.50], 2.34 [1.29‐4.23], and 2.19 [1.21‐3.98], respectively) and elevated but nonstatistically significant ORs for the fourth quartile. Conversely, for PFOA, modest positive associations with ER−, PR−, ER+/PR−, and ER−/PR− tumors were generally seen in the upper quartiles. Our findings contribute evidence supporting positive associations between serum PFOS and hormone receptor‐positive tumors, and possibly between PFOA and receptor‐negative tumors. Future prospective studies incorporating tumor hormone receptor status are needed to better understand the role of PFAS in breast cancer etiology. What's new? Perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) are synthetic chemicals with widespread use in industrial applications and consumer products. They also are endocrine disruptors with suspected links to cancer. Here, the authors investigated potential associations between prediagnostic serum PFOS and PFOA levels and risk of breast cancer subtypes among postmenopausal women. No association was found between PFOS or PFOA and breast cancer risk overall. However, PFOS levels were positively associated with hormone receptor‐positive breast tumors, and modest positive associations were observed between PFOA levels and receptor‐negative tumors. The findings warrant further investigation in studies incorporating breast tumor hormone receptor status.